Author:
Sun Zhihua,Li Qinfeng,Li Zhenyu,Chen Yeshan,Jiang Yao,Wu Gang
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin, 2008, 58: 71–96.
2. Sekine I, Noda K, Oshita F, et al. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci, 2004, 95: 691–695.
3. Phernambucq ECJ, Spoelstra FOB, Verbakel WFAR, et al. Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. Ann Oncol, 2011, 22: 132–138.
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of t he United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92: 205–216.
5. NCI. Common Terminology Criteria for Adverse Events. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 . June 8, 2009.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献